Tags

Type your tag names separated by a space and hit enter

The serum IgA class anti-tissue transglutaminase antibodies in the diagnosis and follow up of coeliac disease. Results of an international multi-centre study. International Working Group on Eu-tTG.
Eur J Gastroenterol Hepatol 2001; 13(6):659-65EJ

Abstract

OBJECTIVES

So far the reliability of the anti-tissue transglutaminase (anti-tTG) test for the diagnosis of coeliac disease has mostly been evaluated using slightly different enzyme-linked immunosorbent assays (ELISAs) in selected and usually small groups of patients. The aims of this study were: (1) to evaluate the reliability of the IgA anti-tTG antibodies for the diagnosis of coeliac disease; and (2) to define the sensitivity and specificity of a commercially available kit for the anti-tTG antibodies' quantitative determination.

DESIGN

Each centre in this international multi-centre study collected sera from three groups of subjects: coeliac disease patients at the onset of (1) or on a gluten-free diet for at least 12 months (2); disease and healthy controls (3).

METHODS

The anti-tTG antibodies were determined in duplicate using an ELISA-based commercially available kit (Eu-tTG Eurospital, Trieste, Italy).

RESULTS

The following overall cases and controls have been enrolled: (1) 399 subjects with active coeliac disease; (2) 351 treated coeliac disease cases; (3) 432 controls. The centralized re-testing was performed on: (1) group a: 176 patients with active coeliac disease (mean anti-tTG, 21 arbitrary units [AU]); (2) group b: 172 treated coeliac disease cases (mean anti-tTG, 5 AU); (3) group c: 206 controls (mean anti-tTG, 3 AU). In active coeliacs, the anti-tTG antibodies showed a significant progressive decrease with age, while in controls an opposite trend was found. In active coeliac disease patients, the anti-tTG antibodies were significantly higher in coeliacs with a grade III enteropathy than in those showing a grade II lesion. In treated coeliacs, the mean anti-tTG values were significantly lower in patients strictly adhering to a gluten-free diet than in those reporting dietary transgressions. The sensitivity and the specificity of the Eu-tTG assay were 90% and 96%, respectively.

CONCLUSION

The results of this study show that the commercially available test for the anti-tTG antibodies' determination is a reproducible and valuable tool for the diagnosis and follow up of coeliac disease.

Authors+Show Affiliations

University of Department of Paediatrics, Ancona, Italy. elisabetta.fab@tiscalinet.it

Pub Type(s)

Clinical Trial
Comparative Study
Controlled Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11434591

Citation

Fabiani, E, et al. "The Serum IgA Class Anti-tissue Transglutaminase Antibodies in the Diagnosis and Follow Up of Coeliac Disease. Results of an International Multi-centre Study. International Working Group On Eu-tTG." European Journal of Gastroenterology & Hepatology, vol. 13, no. 6, 2001, pp. 659-65.
Fabiani E, Catassi C, International Working Group. The serum IgA class anti-tissue transglutaminase antibodies in the diagnosis and follow up of coeliac disease. Results of an international multi-centre study. International Working Group on Eu-tTG. Eur J Gastroenterol Hepatol. 2001;13(6):659-65.
Fabiani, E., & Catassi, C. (2001). The serum IgA class anti-tissue transglutaminase antibodies in the diagnosis and follow up of coeliac disease. Results of an international multi-centre study. International Working Group on Eu-tTG. European Journal of Gastroenterology & Hepatology, 13(6), pp. 659-65.
Fabiani E, Catassi C, International Working Group. The Serum IgA Class Anti-tissue Transglutaminase Antibodies in the Diagnosis and Follow Up of Coeliac Disease. Results of an International Multi-centre Study. International Working Group On Eu-tTG. Eur J Gastroenterol Hepatol. 2001;13(6):659-65. PubMed PMID: 11434591.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The serum IgA class anti-tissue transglutaminase antibodies in the diagnosis and follow up of coeliac disease. Results of an international multi-centre study. International Working Group on Eu-tTG. AU - Fabiani,E, AU - Catassi,C, AU - ,, PY - 2001/7/4/pubmed PY - 2002/1/5/medline PY - 2001/7/4/entrez SP - 659 EP - 65 JF - European journal of gastroenterology & hepatology JO - Eur J Gastroenterol Hepatol VL - 13 IS - 6 N2 - OBJECTIVES: So far the reliability of the anti-tissue transglutaminase (anti-tTG) test for the diagnosis of coeliac disease has mostly been evaluated using slightly different enzyme-linked immunosorbent assays (ELISAs) in selected and usually small groups of patients. The aims of this study were: (1) to evaluate the reliability of the IgA anti-tTG antibodies for the diagnosis of coeliac disease; and (2) to define the sensitivity and specificity of a commercially available kit for the anti-tTG antibodies' quantitative determination. DESIGN: Each centre in this international multi-centre study collected sera from three groups of subjects: coeliac disease patients at the onset of (1) or on a gluten-free diet for at least 12 months (2); disease and healthy controls (3). METHODS: The anti-tTG antibodies were determined in duplicate using an ELISA-based commercially available kit (Eu-tTG Eurospital, Trieste, Italy). RESULTS: The following overall cases and controls have been enrolled: (1) 399 subjects with active coeliac disease; (2) 351 treated coeliac disease cases; (3) 432 controls. The centralized re-testing was performed on: (1) group a: 176 patients with active coeliac disease (mean anti-tTG, 21 arbitrary units [AU]); (2) group b: 172 treated coeliac disease cases (mean anti-tTG, 5 AU); (3) group c: 206 controls (mean anti-tTG, 3 AU). In active coeliacs, the anti-tTG antibodies showed a significant progressive decrease with age, while in controls an opposite trend was found. In active coeliac disease patients, the anti-tTG antibodies were significantly higher in coeliacs with a grade III enteropathy than in those showing a grade II lesion. In treated coeliacs, the mean anti-tTG values were significantly lower in patients strictly adhering to a gluten-free diet than in those reporting dietary transgressions. The sensitivity and the specificity of the Eu-tTG assay were 90% and 96%, respectively. CONCLUSION: The results of this study show that the commercially available test for the anti-tTG antibodies' determination is a reproducible and valuable tool for the diagnosis and follow up of coeliac disease. SN - 0954-691X UR - https://www.unboundmedicine.com/medline/citation/11434591/The_serum_IgA_class_anti_tissue_transglutaminase_antibodies_in_the_diagnosis_and_follow_up_of_coeliac_disease__Results_of_an_international_multi_centre_study__International_Working_Group_on_Eu_tTG_ L2 - http://Insights.ovid.com/pubmed?pmid=11434591 DB - PRIME DP - Unbound Medicine ER -